A drug developer has received $468,000 from the Michael J. Fox Foundation for its Parkinson’s disease therapeutic.
QR Pharma is collaborating with Dr. Robert Nussbaum of the Division of Medical Genetics at the University of California, San Francisco and Dr. Jack T. Rogers of Massachusetts General Hospital, Genetics and Aging Research Unit on its therapeutic, Prosiphen, according to a company statement.
The funding was allocated to QR Pharma as part of the foundation’s Therapeutics Development Initiative for preclinical research for Parkinson’s disease.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
QR Pharma CEO Maria Maccecchini is a serial entrepreneur and her company is based in Berwyn, Pennsylvania.
Prosiphen will be used in studies with mice at San Francisco to determine its effectiveness in mice in reversing gastrointestinal difficulties and motor abnormalities, symptoms similar to what are found in people with Parkinson’s disease. The tests will help establish preclinical efficacy as a basis for future testing in humans, a statement from QR Pharma said.
In addition to Parksinson’s disease, Prosiphen is one of two compounds QR Pharma is developing to treat Alzheimer’s disease.
Last year, Maccecchini received the Iris Newman award from the Alliance of Women Entrepreneurs.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Michael J. Fox Foundation has contributed $275 million to fund research to develop a cure and treat Parkinson’s disease. In February, it launched a partnering program to highlight encouraging research results in the foundation’s portfolio to attract funders to foster development to help drive research projects through the product pipeline.
